Cover Image

Mitochondrial protein IF1 is a potential regulator of glucagon-like peptide (GLP-1) secretion function of the mouse intestine

IF1 (ATPIF1) is a nuclear DNA-encoded mitochondrial protein whose activity is inhibition of the F1Fo-ATP synthase to control ATP production. IF1 activity remains unknown in the regulation of GLP-1 activity. In this study, IF1 was examined in the diet-induced obese mice using the gene knockout (If1-K...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ying Wang (Author), Jiaojiao Zhang (Author), Xinyu Cao (Author), Yaya Guan (Author), Shuang Shen (Author), Genshen Zhong (Author), Xiwen Xiong (Author), Yanhong Xu (Author), Xiaoying Zhang (Author), Hui Wang (Author), Jianping Ye (Author)
Format:	Book
Published:	Elsevier, 2021-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glucagon-like peptide 1 (GLP-1)
by: T.D. Müller, et al.
Published: (2019)

Effects of exercise on glucagon-like peptide-1 (GLP-1)
by: Shin-ya Ueda, et al.
Published: (2013)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
by: Cheng D, et al.
Published: (2022)

Glucagon-Like Peptide-1 (GLP-1) during Ramadan: Narrative Review of the Published Literature
by: Khalid Mohammed Alayed
Published: (2023)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022)

GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
by: Taing MW, et al.
Published: (2014)

IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
by: Nicolaus Bruns VI, et al.
Published: (2024)

Retinal Pigment Epithelial Cells Express a Functional Receptor for Glucagon-Like Peptide-1 (GLP-1)
by: Alessandra Puddu, et al.
Published: (2013)

Effect of glucagon-like peptide-1 (GLP-1) agonists on the example of semaglutide on the cardiovascular system and their role in the treatment of obesity.
by: Kamil Pondel, et al.
Published: (2022)

Beneficial Effects of Glucagon-Like Peptide-1 (GLP-1) in Diabetes-Induced Retinal Abnormalities: Involvement of Oxidative Stress
by: Hugo Ramos, et al.
Published: (2020)

Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus
by: Julianah Ore Abiola, et al.
Published: (2024)

Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS)
by: Sivasenthil Arumugam, et al.
Published: (2024)

Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
by: Wanjun Guo, et al.
Published: (2023)

Myricetin Increases Circulating Adropin Level after Activation of Glucagon-like Peptide 1 (GLP-1) Receptor in Type-1 Diabetic Rats
by: Ying-Xiao Li, et al.
Published: (2022)

Neural regulation of hindlimb muscle contraction-induced glucagon-like peptide-1 and peptide YY secretion in rats
by: Shin-ya Ueda, et al.
Published: (2015)

Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs
by: Anubhav Pratap-Singh, et al.
Published: (2023)

Use of Glucagon-like peptide 2 (GLP-2) analogs in inflammatory bowel disease
by: Dobromiła Osuch, et al.
Published: (2024)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017)

Antioxidant, Physicochemical, and Cellular Secretion of Glucagon-Like Peptide-1 Properties of Oat Bran Protein Hydrolysates
by: Mallory E. Walters, et al.
Published: (2020)

L-cell Arntl is required for rhythmic glucagon-like peptide-1 secretion and maintenance of intestinal homeostasis
by: Sarah E. Martchenko, et al.
Published: (2021)

Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies
by: Fanjing Kong, et al.
Published: (2023)

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist S6 Stimulates Insulin Secretion From Rat Islets
by: Xiaohua Yang, et al.
Published: (2021)

Biochemical Investigation of Therapeutic Potentials of Plant-Based Bioactive Compounds as Stimulators of Glucagon like peptide-1 Secretion
by: Areeba Javed, et al.
Published: (2022)

Mechanistic insights into the detection of free fatty and bile acids by ileal glucagon-like peptide-1 secreting cells
by: Deborah A. Goldspink, et al.
Published: (2018)

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
by: Sigrid Jall, et al.
Published: (2017)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024)

Tocopheryl quinone improves non-alcoholic steatohepatitis (NASH) associated dysmetabolism of glucose and lipids by upregulating the expression of glucagon-like peptide 1 (GLP-1) via restoring the balance of intestinal flora in rats
by: Tao Sun, et al.
Published: (2021)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)
by: Stav Brown, et al.
Published: (2024)

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension
by: Hae Young Lee, et al.
Published: (2024)

Electrophilic Agonists Modulate the Transient Receptor Potential Ankyrin-1 Channels Mediated by Insulin and Glucagon-like Peptide-1 Secretion for Glucose Homeostasis
by: Marisa Jadna Silva Frederico, et al.
Published: (2023)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022)

Human islets contain a subpopulation of glucagon-like peptide-1 secreting α cells that is increased in type 2 diabetes
by: Scott A. Campbell, et al.
Published: (2020)

Regulation of microbiotaGLP1 axis by sennoside A in diet-induced obese mice
by: Jiamei Le, et al.
Published: (2019)

Kazak faecal microbiota transplantation induces short-chain fatty acids that promote glucagon-like peptide-1 secretion by regulating gut microbiota in db/db mice
by: Xue Han, et al.
Published: (2021)

The core clock gene, Bmal1, and its downstream target, the SNARE regulatory protein secretagogin, are necessary for circadian secretion of glucagon-like peptide-1
by: Andrew D. Biancolin, et al.
Published: (2020)

Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management
by: Mariya Kalinkova, et al.
Published: (2023)

Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis
by: Qian Zhao, et al.
Published: (2024)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024)

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
by: Xinrui Tan, et al.
Published: (2023)